Descriptive characteristics of the study population
| Variables | n = 370 |
| Age (years) | 80.9 (7.9) |
| Males, n (%) | 207 (56%) |
| Prior atrial fibrillation, n (%) | 154 (42%) |
| STS score | 8.3 (5.0) |
| NYHA class IV, n (%) | 104 (28%) |
| Diabetes, n (%) | 153 (41%) |
| Dyslipidemia, n (%) | 333 (90%) |
| Hypertension, n (%) | 333 (90%) |
| History of stroke/TIA, n (%) | 33 (9%) |
| Peripheral vascular disease, n (%) | 220 (59%) |
| Moderate/severe renal disease, n (%) | 246 (66%) |
| Prior CABG, n (%) | 161 (44%) |
| Previous MI, n (%) | 137 (37%) |
| Prior valve intervention, n (%) | 73 (20%) |
| Pre-TAVR medications | |
| Antiarrhythmics, n (%) | 32 (9%) |
| Aspirin, n (%) | 271 (73%) |
| Coumadin, n (%) | 22 (6%) |
| Echocardiographic parameters | |
| Ejection fraction | 56.3 (13.5) |
| Pulmonary artery systolic pressure (mm Hg) | 43.9 (14.3) |
| Left atrial volume index (cc/m2) | 48.9 (14.9) |
| Aortic valve area | 0.8 (0.2) |
| Mean systolic aortic valve gradient | 49.4 (13.2) |
| Moderate/severe MR (%) | 96 (27%) |
| CT scan | |
| Severity of aortic atherosclerosis, n (%) | |
| None, trivial or mild | 164 (53%) |
| Mild-to-moderate or moderate | 106 (34%) |
| Moderate-to-severe or severe | 40 (13%) |
| CT aortic valve calcium score | 2966.5 (1633.4) |
CABG, coronary artery bypass surgery; MR, mitral regurgitation; MI, myocardial infarction; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; TIA, transient ischaemic attack; TAVR, transcatheter aortic valve replacement.